TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04092660

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behaviour change Intervention Based on Health Action Process Approach Model
Description: The Behaviour change intervention based on the Health Action Process Approach model entails delivering interventions in a staged manner. Following are the intervention that will be delivered along with the time point of the delivery.~1. Health Pamphlet at the initial screening~2. Sleep Apnoea video highlighting the negative consequences at the day of the fitting of the appliance~3. Counseling involving motivational interviewing for both the participant and the participant's partner at the day of fitting of the appliance and follow up visits.~4. Booster phone calls in between the follow-up visits

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mandibular Advancement Appliance (MAA) or Anti-snoring mouth guard
Description: Patients with mild-to-moderate sleep apnoea are treated with Mandibular Advancement Appliances \[MAA\] also known as Anti-snoring mouth guards or Oral appliances. These are best made to fit and use the teeth to hold them in place during sleep. They work by moving (in a gradual fashion) the bottom jaw forward, opening the airway at the back of the throat.~Both the arms- Intervention arm and Standardized arm will be given the anti-snoring mouth guard. The usage of the device will be measured subjectively by providing a sleep diary to the participants to record the hour of the usage and objectively by downloading the data from a micro sensor chip embedded in the device.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Mandibular Advancement Appliance (MAA) or Anti-snoring mouth guard
Description: Patients with mild-to-moderate sleep apnoea are treated with Mandibular Advancement Appliances \[MAA\] also known as Anti-snoring mouth guards or Oral appliances. These are best made to fit and use the teeth to hold them in place during sleep. They work by moving (in a gradual fashion) the bottom jaw forward, opening the airway at the back of the throat.~Both the arms- Intervention arm and Standardized arm will be given the anti-snoring mouth guard. The usage of the device will be measured subjectively by providing a sleep diary to the participants to record the hour of the usage and objectively by downloading the data from a micro sensor chip embedded in the device.
Study: NCT02132611

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Diamondback 360® Coronary OAS Micro Crown
Description: The Diamondback 360® Coronary OAS Micro Crown consists of a diamond-coated crown mounted to a shaft. The OAD ablates occlusive material in order to facilitate stent delivery. During orbit, forces press the crown against the coronary plaque, reducing calcified plaque on the vessel wall.
Study: NCT02005471

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bendamustine
Description: Bendamustine will be administered at a dose of 70 mg/m\^2 via IV infusion on Days 1 and 2 of each 28-day cycle, for 6 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Venetoclax will be administered at an initial dose of 20 mg via tablet orally QD, incremented weekly up to a maximum dose of 400 mg during a 5-week ramp-up period. Venetoclax will be continued at 400 mg QD from Week 6 (Day 1 of Cycle 1 of combination therapy) onwards up to disease progression (PD) or 2 years, whichever occurs first.~R/C Substudy: venetoclax will be administered for 5-week dose ramp-up period to reach the target dose of 400 mg QD. Venetoclax will continue to be administered during the rituximab cycles until disease progression or for a maximum of 2 years from Cycle 1R/C Day 1 of the R/C Substudy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Venetoclax will be administered at an initial dose of 20 mg via tablet orally QD, incremented weekly up to a maximum dose of 400 mg during a 5-week ramp-up period. Venetoclax will be continued at 400 mg QD from Week 6 (Day 1 of Cycle 1 of combination therapy) onwards up to disease progression (PD) or 2 years, whichever occurs first.~R/C Substudy: venetoclax will be administered for 5-week dose ramp-up period to reach the target dose of 400 mg QD. Venetoclax will continue to be administered during the rituximab cycles until disease progression or for a maximum of 2 years from Cycle 1R/C Day 1 of the R/C Substudy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Venetoclax will be administered at an initial dose of 20 mg via tablet orally QD, incremented weekly up to a maximum dose of 400 mg during a 5-week ramp-up period. Venetoclax will be continued at 400 mg QD from Week 6 (Day 1 of Cycle 1 of combination therapy) onwards up to disease progression (PD) or 2 years, whichever occurs first.~R/C Substudy: venetoclax will be administered for 5-week dose ramp-up period to reach the target dose of 400 mg QD. Venetoclax will continue to be administered during the rituximab cycles until disease progression or for a maximum of 2 years from Cycle 1R/C Day 1 of the R/C Substudy.
Study: NCT01523678

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: All subjects will receive standard treatment with paclitaxel followed by carboplatin intravenously during 18 weeks. Filgrastim (Neupogen) will be given prophylactically on day 5. An additional dose will be given on day 6 in case of severe neutropenia during the course of the trial.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: All subjects will receive standard treatment with paclitaxel followed by carboplatin intravenously during 18 weeks. Filgrastim (Neupogen) will be given prophylactically on day 5. An additional dose will be given on day 6 in case of severe neutropenia during the course of the trial.
Study: NCT02522754

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Experimental: Protesomal Vaccine 1 x 30 µg
Description: Experimental: Protesomal Vaccine 1 x 30 µg

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Experimental: Protesomal Vaccine 2 x 30 µg
Description: Experimental: Protesomal Vaccine 2 x 30 µg

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Experimental: Protesomal Vaccine 2 x 15 µg
Description: Experimental: Protesomal Vaccine 2 x 15 µg
Study: NCT02514031

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARQ-761
Description: Dose Level 1:~ARQ761 195 mg IV D1, D15 Gemcitabine 1000 mg/m2 D1, 8, 15 Nab paclitaxel 125 mg/m2 D1, 8, 15~Dose Level 2:~ARQ761 290 mg IV D1, D15 Gemcitabine 1000 mg/m2 D1,8,15~Dose Level 3:~ARQ761 390 mg IV D1, D15 Gemcitabine 1000 mg/m2 D1,8,15 Nab-paclitaxel 125 mg/m2 D1,8,15~Expansion Dose Level:~ARQ761 390 IV mg or as tolerated D1, 15 Gemcitabine 1000 mg/m2 D1,8,15 Nab-Paclitaxel 125 mg/m2 D1,8,15

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Therapy after lead in Phase:~You will receive Gemcitabine (1000mg/m2) administered intravenously on Days 1,8, 15-every 28 days. All cycles are 28 days in duration and there are no rest periods between cycles. You may continue treatment after cycle 6 until disease progression.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-paclitaxel
Description: Therapy after lead in phase:~You will receive nab-paclitaxel (125 mg/m2) administered intravenously on Days 1,8, 15-every 28 days. All cycles are 28 days in duration and there are no rest periods between cycles. You may continue treatment after cycle 6 until disease progression.
Study: NCT01217112

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GWP42003
Description: 100 mg capsules, PO, BD, 91 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GWP42003
Description: 100 mg capsules, PO, BD, 91 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GWP42003
Description: 5 mg capsules, PO, BD, 91 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GWP42004
Description: 5 mg capsules, PO, BD, 91 days
Study: NCT03984136

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: COHIV with exchange mechanism
Description: A WeChat-based mini program has been developed to send and receive Center for Disease Control and Prevention certified online HIV results (COHIV). WeChat is the ubiquitous communication and social networking tool in China. Participants in the intervention group will receive his friend's COHIV only when the participants share their own in exchange. If the participant already has the COHIV, the system will lead the user to send his COHIV to the friend. If the participant does not have the COHIV, the system will guide him to make online appointment at the testing clinic.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: COHIV without exchange mechanism
Description: The participants in the control group will be able to receive the friend's Center for Disease Control and Prevention certified online HIV results (COHIV) entirely at the friend's discretion without the mandatory exchange requirement. The system will also guide users on how to get an HIV test by making appointments with the MSM friendly clinics in the mini program.
Study: NCT03605537

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug-eluting Stent Mometasone
Description: The subject will have a mometasone drug-eluting stent placed during their choanal atresia repair procedure instead of no stent being placed.
Study: NCT05612737

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Horizontal bone augmentation
Description: After taking six 9 mL tubes of blood from the patient, advanced (A-PRF) and liquid (S-PRF) PRFs were prepared. A-PRF was chopped, added to the xenogeneic bone substitute (THE Graft; Purgo Biologics Inc.), and then impregnated with the liquid S-PRF, which enabled the particulate bone substitute to become moldable and turned into a block (sticky bone). After local anesthesia, a midcrestal incision was made with one vertical releasing incision at the flap's mesial end. After full-thickness flap elevation, a periosteal releasing incision was made at the flap's apical portion. The alveolar bone was decorticalized on the buccal aspect with surgical burs. Next, the prepared bonded graft matrix was adapted to the ridge. Then, tenting screws (Pro-fix; Osteogenics) were placed to maintain the periosteum in an elevated and tension-free position The bone augmentation material was covered with A-PRF membranes. Finally, tension-free wound closure was performed.
Study: NCT03880331

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Debridement
Description: Aggressive vs Minimal Debridement

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Debridement
Description: Aggressive vs Minimal Debridement
Study: NCT00821457

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Juvista
Description: 250ng

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Powder for solution for injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Powder for solution for injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Juvista
Description: 500ng
Study: NCT01807962

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rapidocain and bethametsaone
Description: lidocaine (Rapidocain(R)): 4ml of 1% Lidocaine~bethametasone (Diprophos): 1ml ampoule (containing 5mg/ml dipropionate de betamethasone and 2mg/ml phosphate disodique de betamethasone)
Study: NCT01217112

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GWP42004
Description: 5 mg capsules, PO, BD, 91 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GWP42004
Description: 5 mg capsules, PO, BD, 91 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: 0 mg capsules, QDS, PO, 91 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: 0 mg capsules, QDS, PO, 91 days
Study: NCT02005471

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: Rituximab will be administered at a dose of 375 mg/m\^2 via IV infusion on Day 1 of Cycle 1 and at a dose of 500 mg/m\^2 on Day 1 of Cycles 2-6.~R/C Substudy: Following the venetoclax ramp-up period, rituximab will be administered for 6 cycles consisting of a single infusion on the first day of each 28-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab will be administered at a dose of 375 mg/m\^2 via IV infusion on Day 1 of Cycle 1 and at a dose of 500 mg/m\^2 on Day 1 of Cycles 2-6.~R/C Substudy: Following the venetoclax ramp-up period, rituximab will be administered for 6 cycles consisting of a single infusion on the first day of each 28-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab will be administered at a dose of 375 mg/m\^2 via IV infusion on Day 1 of Cycle 1 and at a dose of 500 mg/m\^2 on Day 1 of Cycles 2-6.~R/C Substudy: Following the venetoclax ramp-up period, rituximab will be administered for 6 cycles consisting of a single infusion on the first day of each 28-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab will be administered at a dose of 375 mg/m\^2 via IV infusion on Day 1 of Cycle 1 and at a dose of 500 mg/m\^2 on Day 1 of Cycles 2-6.~R/C Substudy: Following the venetoclax ramp-up period, rituximab will be administered for 6 cycles consisting of a single infusion on the first day of each 28-day cycle.
Study: NCT01807962

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: sterile saline
Description: Placebo = 5ml of sterile saline solution
Study: NCT01864720

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Professionally-administered cognitive-behavioral therapy for insomnia (CBT-I)
Description: The treatment content will be the same whether it is administered by a professional or self-administered. This multimodal approach combines behavioural (i.e., stimulus control therapy, sleep restriction), cognitive (i.e., cognitive restructuring), and educational (i.e., sleep hygiene) strategies that are administered over a 6-week period.
Study: NCT03136614

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Arteriograph

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Arteriograph

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Arteriograph
Study: NCT00898677

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rizatriptan benzoate
Description: single dose administration of 5mg rizatriptan (by Mouth) p.o.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rizatriptan benzoate
Description: single dose administration of 10 mg rizatriptan p.o.
Study: NCT01864720

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Professionally-administered cognitive-behavioral therapy for insomnia (CBT-I)
Description: The treatment content will be the same whether it is administered by a professional or self-administered. This multimodal approach combines behavioural (i.e., stimulus control therapy, sleep restriction), cognitive (i.e., cognitive restructuring), and educational (i.e., sleep hygiene) strategies that are administered over a 6-week period.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Web-based cognitive-behavioral therapy for insomnia (CBT-I)
Description: The treatment content will be the same whether it is administered by a professional or self-administered. Each week, the patients will first have to read written information on the website, and then watch a video capsule (duration between 5 and 20 min each). The treatment material will be identical to the video (DVD)-based CBT-I that we previously developed. Patients will complete their daily sleep diary electronically on the website and the content will be interactive. It will include the sending of automated emails to remind participants to complete the treatment tasks and encourage adherence, provision of tailored feedback (e.g., texts, charts) based on the information that they provide in their sleep diary, as well as quizzes with automated correction to reinforce patients' understanding of the content.
Study: NCT02718976

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound/MR image fusion guided lumbar plexus block (Shamrock)

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Ultrasound guided lumbar plexus block (Shamrock)

Intervention type: DRUG
Group type: OTHER
Intervention: Lidocaine-epinephrine added gadoterate meglumine
Description: Perineural injection of 20 ml 2% lidocaine with 0.0005% epinephrine added 1 ml of gadoterate meglumine (0.13 ml) and sodium chloride (NaCl, 0.87 ml). The 1 ml of gadoterate meglumine-NaCl is added to the local anesthetic prior to the perineural injection in order to enhance visualization of the local anesthetic on MRI scanning after the intervention.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine-epinephrine added gadoterate meglumine
Description: Perineural injection of 20 ml 2% lidocaine with 0.0005% epinephrine added 1 ml of gadoterate meglumine (0.13 ml) and sodium chloride (NaCl, 0.87 ml). The 1 ml of gadoterate meglumine-NaCl is added to the local anesthetic prior to the perineural injection in order to enhance visualization of the local anesthetic on MRI scanning after the intervention.
Study: NCT01999231

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ESAT6-CFP10
Description: 32 healthy subjects who meet the standard of protocol are allocated four different groups according to dosages of ESAT6-CFP10 :1μg/ml ESAT6-CFP10、5μg/ml ESAT6-CFP10、10μg/ml ESAT6-CFP10、20μg/ml ESAT6-CFP10.Each dose group have six healthy subjects(three male and three female) , at the same time set up two people for substitute (one male and one female) . ESAT6-CFP10 administered intradermally by the mantoux injection technique. Each receives only one dosage in right or left arm .

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ESAT6-CFP10
Description: 32 healthy subjects who meet the standard of protocol are allocated four different groups according to dosages of ESAT6-CFP10 :1μg/ml ESAT6-CFP10、5μg/ml ESAT6-CFP10、10μg/ml ESAT6-CFP10、20μg/ml ESAT6-CFP10.Each dose group have six healthy subjects(three male and three female) , at the same time set up two people for substitute (one male and one female) . ESAT6-CFP10 administered intradermally by the mantoux injection technique. Each receives only one dosage in right or left arm .

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ESAT6-CFP10
Description: 32 healthy subjects who meet the standard of protocol are allocated four different groups according to dosages of ESAT6-CFP10 :1μg/ml ESAT6-CFP10、5μg/ml ESAT6-CFP10、10μg/ml ESAT6-CFP10、20μg/ml ESAT6-CFP10.Each dose group have six healthy subjects(three male and three female) , at the same time set up two people for substitute (one male and one female) . ESAT6-CFP10 administered intradermally by the mantoux injection technique. Each receives only one dosage in right or left arm .

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ESAT6-CFP10
Description: 32 healthy subjects who meet the standard of protocol are allocated four different groups according to dosages of ESAT6-CFP10 :1μg/ml ESAT6-CFP10、5μg/ml ESAT6-CFP10、10μg/ml ESAT6-CFP10、20μg/ml ESAT6-CFP10.Each dose group have six healthy subjects(three male and three female) , at the same time set up two people for substitute (one male and one female) . ESAT6-CFP10 administered intradermally by the mantoux injection technique. Each receives only one dosage in right or left arm .
Study: NCT00567528

Intervention type: DRUG
Group type: OTHER
Intervention: Ibuprofen
Description: Apply by rubbing into skin for 30 to 60 seconds placebo ibuprofen 10% gel, 0.5cc to skin over injured area 3 times a day and taking active capsules of ibuprofen 3 times a day 10-40mg/kg per day, not to exceed 1200mg per day for 2 weeks.

Intervention type: DRUG
Group type: OTHER
Intervention: ibuprofen
Description: Apply by rubbing into skin for 30 to 60 seconds active ibuprofen 10% gel, 0.5cc to skin over injured area 3 times a day and taking placebo capsules of ibuprofen 3 times a day 10-40mg/kg per day, not to exceed 1200mg per day for 2 weeks.
Study: NCT04331652

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Polypectomy without anesthesia or analgo-sedation
Description: Premedication: paracetamol 1g oral. Patient will undergo polypectomy without anesthesia. During the procedure, pain will be monitored using a pain assessment scale from 0 to 10 (0 meaning no pain and 10 meaning maximum pain imaginable). At any time, if the patient express a pain strictly superior to 4 an analgo-sedation will be proposed and/or general anesthesia.~Pulse and blood pressure will be monitored. Assessment of patient satisfaction after the intervention.
Study: NCT06531265

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endobronchial cryobiopsy and cryotherapy using flexible bronchoscopy
Description: Bronchoscopic evaluation of endobronchial lesion with biopsy and cryotherapy for recanalisation
Study: NCT00438958

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: filgrastim
Description: Given on day 0.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Description: Given on day 0.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: allogeneic bone marrow transplantation
Description: Given on day 0

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: peripheral blood stem cell transplantation
Description: Given on day 0
Study: NCT04888260

Intervention type: OTHER
Intervention: Laboratory parameter levels in blood samples
Description: Mannose and lipid parameters (triglyceride, LDL, HDL, VLDL) will be analysed in blood samples by using ELISA method.

Intervention type: OTHER
Intervention: Laboratory parameter levels in blood samples
Description: Mannose and lipid parameters (triglyceride, LDL, HDL, VLDL) will be analysed in blood samples by using ELISA method.
Study: NCT01076166

Intervention type: DRUG
Intervention: clarithromycin (Klacid) granules for oral suspension
Description: clarithromycin (Klacid) Granules for Oral Suspension
Study: NCT00872391

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hypofractionated linear accelerator radiotherapy
Description: 10 fractions of stereotactic linear accelerator radiotherapy with 6 Gy per fraction at the 80% isodose for the planning target volume.
Study: NCT06056700

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education
Description: All study follow-up information was collected through this app. The information offered to all the mothers through the mobile application contained a welcome message, contact data, sociodemographic and clinical variables, and access to the TMM-24 questionnaire. However, the GI through the app had access to complementary information content regarding the CG. The mothers of the IG had additional training material related to the first two prenatal face-to-face training sessions and new information during the postnatal period throughout consecutive weeks 1 to 8.
Study: NCT02343016

Intervention type: DEVICE
Intervention: Near-InfraRed Spectroscopy (NIRS)
Description: NIRS is a non invasive monitoring system that enables assessment of tissue oxygenation through a quantitative estimation of haemoglobin oxygen-saturation within tissues.
Study: NCT00606879

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SGX523 Capsules
Description: This is a dose escalation study